Shandong Langnuo Pharmaceutical Co. Ltd.

Primary objective: To evaluate the pharmacokinetic (PK) similarity between a single fasting administration of the test formulation SH081012 oral concentrate 500 mg (3 mL: 1 g) provided by Shandong Bainuo Pharmaceutical Co., Ltd., and the reference formulation chloral hydrate/syrup combination package 500 mg [chloral hydrate concentrate 1.342 g: 1 g/syrup (diluent) 9 mL] manufactured by Tefeng Pharmaceutical Co., Ltd., and to assess their relative bioavailability. Secondary objective: To evaluate the safety, pharmacodynamics, taste, and irritation of the test formulation SH081012 oral concentrate provided by Shandong Bainuo Pharmaceutical Co., Ltd.

Primary objective: To investigate the pharmacokinetics of a single oral dose of the test formulation, vardenafil hydrochloride orally disintegrating tablets (10 mg; manufactured by Shandong Langnuo Pharmaceutical Co., Ltd.), and the reference formulation, vardenafil hydrochloride orally disintegrating tablets (10 mg; manufactured by Alembic Pharmaceuticals Limited), in healthy adult male participants under fasting conditions, and to evaluate the bioequivalence of the two formulations under fasting conditions. Secondary objective: To assess the safety of the test formulation, vardenafil hydrochloride orally disintegrating tablets (10 mg), and the reference formulation, vardenafil hydrochloride orally disintegrating tablets (10 mg), in healthy male participants.

Primary objective: To investigate the pharmacokinetics of a single oral dose of the test formulation atorvastatin calcium oral suspension (150 ml: 0.6 g (C33H35FN2O5); manufacturer: Shandong Langnuo Pharmaceutical Co., Ltd.) and the reference formulation Atorvaliq® (20 mg/5 ml; licensee: CMP DEVELOPMENT LLC) in healthy adult participants under fasting conditions, and to evaluate the bioequivalence of the two formulations under fasting conditions. Secondary objective: To evaluate the safety of the test formulation atorvastatin calcium oral suspension (150 ml: 0.6 g (C33H35FN2O5)) and the reference formulation Atorvaliq® (20 mg/5 ml) in healthy adult participants.